Quidel Corporation (Nasdaq: QDEL) is a worldwide leader in developing, manufacturing and marketing point-of-care (POC) rapid diagnostic tests for the detection and management of a variety of medical conditions and illnesses. In the U.S., Quidel leads the market in several POC product categories for sales through medical product distributors.

Its products provide healthcare professionals with accurate and cost-effective diagnostic information at the POC. Quidel's product base and technology platforms have expanded through internal development and acquisitions of other products and technologies. During the early 1990's, Quidel successfully embarked on a mission to build its own branded business and market franchises in the professional use markets. As a result, the company enjoys excellent product recognition in its target markets.

The strength of Quidel's international distribution strategy was reflected in the successful launch of the RapidVue Influenza test in Japan, the world's second largest flu market. It is extending the QuickVue brand in selected Asian and European markets, and will use the Japanese market roll-out as a template for penetrating additional countries with appropriate products.

QuickVue ® Influenza A+B Rapid Test